Inventor · disambiguated record
Andreas Hohlbaum
Also filed as: HOHLBAUM ANDREAS · HOHLBAUM ANDREAS MICHAEL
22 granted patents·11 pending applications·168 citations·filing 2002–2022
95Inventor score
Files withPIERIS PHARMACEUTICALS GMBH15PIERIS AG4MATSCHINER GABRIELE3ASTRAZENECA AB2DAIICHI SANKYO CO LTD2
Top patents by PatentIndex Score
33 records- 0194US9260492B2Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)MATSCHINER GABRIELE·Filed 2011·Granted Feb 16, 2016·27 cites·18 claims
- 0293US10857202B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Dec 8, 2020·4 cites·18 claims
- 0392US11382951B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2020·Granted Jul 12, 2022·2 cites·19 claims
- 0490US10016483B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Jul 10, 2018·6 cites·20 claims
- 0590US9051382B2Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins that bind hepcidin and nucleic acid encoding suchTRENTMANN STEFAN·Filed 2011·Granted Jun 9, 2015·26 cites·13 claims
- 0689US10046027B2Muteins of tear lipocalin and methods for obtaining the samePIERIS PHARMACEUTICALS GMBH·Filed 2015·Granted Aug 14, 2018·8 cites·14 claims
- 0788US8313924B2Muteins of tear lipocalin and methods for obtaining the sameJENSEN KRISTIAN·Filed 2007·Granted Nov 20, 2012·14 cites·44 claims
- 0888US7892827B2Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)PIERIS AG·Filed 2005·Granted Feb 22, 2011·21 cites·18 claims
- 0987US10898545B2Tear lipocalin muteins binding IL-4 r alphaASTRAZENECA AB·Filed 2019·Granted Jan 26, 2021·2 cites·15 claims
- 1087US10398754B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2018·Granted Sep 3, 2019·4 cites·19 claims
- 1187US9687524B2Tear lipocalin muteins binding IL-4 R alphaPIERIS PHARMACEUTICALS GMBH·Filed 2015·Granted Jun 27, 2017·6 cites·7 claims
- 1286US9221885B2Muteins of human lipocalin 2 with affinity for CTLA-4MATSCHINER GABRIELE·Filed 2011·Granted Dec 29, 2015·6 cites·18 claims
- 1385US8986951B2Tear lipocalin in muteins binding IL-4 R alphaHOHLBAUM ANDREAS·Filed 2011·Granted Mar 24, 2015·13 cites·21 claims
- 1483US10232014B2Tear lipocalin muteins binding IL-4 R alphaPIERIS PHARMACEUTICALS GMBH·Filed 2017·Granted Mar 19, 2019·3 cites·25 claims
- 1583US9572863B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2012·Granted Feb 21, 2017·4 cites·20 claims
- 1683US9212208B2Muteins with tear lipocalin having affinity to human c-Met receptor tyrosine kinase and methods for obtaining the sameMATSCHINER GABRIELE·Filed 2009·Granted Dec 15, 2015·6 cites·22 claims
- 1782US9950034B2Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulationPIERIS PHARMACEUTICALS GMBH·Filed 2017·Granted Apr 24, 2018·3 cites·20 claims
- 1882US9610356B2Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulationPIERIS PHARMACEUTICALS GMBH·Filed 2012·Granted Apr 4, 2017·7 cites·23 claims
- 1981US9221887B2Muteins of tear lipocalin and methods for obtaining the sameJENSEN KRISTIAN·Filed 2012·Granted Dec 29, 2015·5 cites·14 claims
- 2079US2023021168A1Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 2172US2021196788A1Tear lipocalin muteins binding il-4 r alphaASTRAZENECA AB·Filed 2020·Application pending·0 cites
- 2269US9150629B2Human tear lipocalins which bind PCSK9 and methods of use thereofPIERIS AG·Filed 2014·Granted Oct 6, 2015·1 cites·56 claims
- 2359US2019015477A1Muteins of tear lipocalin and methods for obtaining the samePIERIS PHARMACEUTICALS GMBH·Filed 2018·Application pending·0 cites
- 2456US2009274623A1In vivo imaging agents for met receptor tyrosine kinaseGEN ELECTRIC·Filed 2008·Application pending·0 cites
- 2555US2018311311A1Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulationPIERIS PHARMACEUTICALS GMBH·Filed 2018·Application pending·0 cites
- 2652US2017369542A1Human neutrophil gelatinase-associated lipocalin (hngal) muteins that bind hepcidin and nucleic acid encoding suchPIERIS PHARMACEUTICALS GMBH·Filed 2017·Application pending·0 cites
- 2750US9598476B2Nucleic acid molecules encoding muteins of human tear lipocalin which bind PCSK9DAIICHI SANKYO CO LTD·Filed 2015·Granted Mar 21, 2017·0 cites·51 claims
- 2850US2017173112A1Novel binding proteins for pcsk9DAIICHI SANKYO CO LTD·Filed 2017·Application pending·0 cites
- 2949US9751920B2Muteins with tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the samePIERIS PHARMACEUTICALS GMBH·Filed 2015·Granted Sep 5, 2017·0 cites·2 claims
- 3048US2015369821A1Novel lipocalin-mutein assays for measuring hepcidin concentrationPIERIS AG·Filed 2014·Application pending·0 cites
- 3146US2015291675A1Human neutrophil gelatinase-associated lipocalin (hngal) muteins that bind hepcidin and nucleic acid encoding suchPIERIS AG·Filed 2015·Application pending·0 cites
- 3237US2003148454A1Virus-free vesicles for delivery of functional membrane bound proteinsUNIV BOSTON·Filed 2002·Application pending·0 cites
- 3330US2012201873A1Controlled release formulations of lipocalin muteinsHOHLBAUM ANDREAS·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Andreas Hohlbaum files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →